[go: up one dir, main page]

AU2001274009A1 - Substituted indoles as parp inhibitors - Google Patents

Substituted indoles as parp inhibitors

Info

Publication number
AU2001274009A1
AU2001274009A1 AU2001274009A AU7400901A AU2001274009A1 AU 2001274009 A1 AU2001274009 A1 AU 2001274009A1 AU 2001274009 A AU2001274009 A AU 2001274009A AU 7400901 A AU7400901 A AU 7400901A AU 2001274009 A1 AU2001274009 A1 AU 2001274009A1
Authority
AU
Australia
Prior art keywords
parp inhibitors
substituted indoles
indoles
substituted
parp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274009A
Inventor
Roland Grandel
Thomas Hoger
Uta Holzenkamp
Michael Kock
Wilfried Lubisch
Reinhold Muller
Sabine Schult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
B A S F A G
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B A S F A G, BASF SE filed Critical B A S F A G
Publication of AU2001274009A1 publication Critical patent/AU2001274009A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2001274009A 2000-05-11 2001-05-09 Substituted indoles as parp inhibitors Abandoned AU2001274009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10022925A DE10022925A1 (en) 2000-05-11 2000-05-11 New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
DE10022925 2000-05-11
PCT/EP2001/005278 WO2001085687A1 (en) 2000-05-11 2001-05-09 Substituted indoles as parp inhibitors

Publications (1)

Publication Number Publication Date
AU2001274009A1 true AU2001274009A1 (en) 2001-11-20

Family

ID=7641548

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274009A Abandoned AU2001274009A1 (en) 2000-05-11 2001-05-09 Substituted indoles as parp inhibitors

Country Status (8)

Country Link
US (1) US7087637B2 (en)
EP (1) EP1280774A1 (en)
JP (1) JP2003532709A (en)
AU (1) AU2001274009A1 (en)
CA (1) CA2408369A1 (en)
DE (1) DE10022925A1 (en)
MX (1) MXPA02010985A (en)
WO (1) WO2001085687A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022925A1 (en) 2000-05-11 2001-11-15 Basf Ag New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JPWO2003062234A1 (en) * 2002-01-23 2005-05-19 山之内製薬株式会社 Quinoxaline compounds
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
CA2537097A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US8060112B2 (en) 2003-11-20 2011-11-15 Intellient Spatial Technologies, Inc. Mobile device and geographic information system background and summary of the related art
PT2305221E (en) 2003-12-01 2015-09-03 Cancer Res Inst Dna damage repair inhibitors for treatment of cancer
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
MX2007008771A (en) 2005-01-19 2007-09-11 Mgi Gp Inc Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp.
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2007113596A1 (en) * 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
TWI404716B (en) 2006-10-17 2013-08-11 Kudos Pharm Ltd Phthalazinone derivative
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
KR20100059950A (en) 2007-09-14 2010-06-04 아스트라제네카 아베 Phthalazinone derivatives
EP2209375B1 (en) 2007-10-03 2014-08-27 Eisai Inc. Parp inhibitor compounds, compositions and methods of use
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
AU2009300866B2 (en) * 2008-10-07 2013-03-28 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
ME02757B (en) 2010-05-07 2018-01-20 Glaxosmithkline Llc INDOLES
WO2012075080A1 (en) * 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
KR101528688B1 (en) 2010-12-02 2015-06-12 상하이 드 노보 파마테크 컴퍼니 리미티드 Heterocyclic derivatives, preparation processes and medical uses thereof
US9242962B2 (en) 2011-11-04 2016-01-26 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
KR101827444B1 (en) * 2012-02-01 2018-02-08 제일약품주식회사 Crystalline acid-added salt of tircyclo derivatives compound or hydrate thereof and preparation thereof
CN103242273B (en) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-arylbenzofuran-7-methanamide compound, preparation method and application thereof
CN102627620B (en) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 One class benzofuran derivative and medical applications thereof
ME03307B (en) * 2013-06-26 2019-10-20 Abbvie Inc Primary carboxamides as btk inhibitors
JP6871169B2 (en) 2015-03-02 2021-05-12 シナイ ヘルス システム Homologous recombination factor
EP3594343B1 (en) 2015-07-23 2021-04-21 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
JP7534218B2 (en) 2018-03-13 2024-08-14 ヴァレリオ・セラピューティクス DBAIT molecules combating acquired resistance in cancer treatment
JP2022504228A (en) 2018-10-03 2022-01-13 テサロ， インコーポレイテッド Crystal form of niraparib free base
CN109574986B (en) * 2019-01-23 2020-10-27 聊城大学 6-Aminobenzo[b]thiophene-2-carboxylic acid derivatives and their application in antiepileptic
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024233875A2 (en) * 2023-05-11 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Heterocyclic compounds for imaging aggregated tau in tauopathies
CN121398822A (en) 2023-06-21 2026-01-23 四方生物科学有限公司 Combinations comprising deoxycytidine derivatives and PARP inhibitors for use in methods of treating cancers with normal heart rate function.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123147A (en) * 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives and their use
BR9710230A (en) * 1996-07-09 1999-08-10 Smithkline Beecham Spa Indole derivatives for the treatment of osteoporosis
EP0927167A1 (en) * 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
DE19636150A1 (en) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
HK1041694A1 (en) 1998-11-17 2002-07-19 巴斯福股份公司 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6831095B1 (en) * 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
GB0000625D0 (en) * 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
DE10009000A1 (en) * 2000-02-25 2001-08-30 Basf Ag Process for the preparation of substituted indoles
DE10022925A1 (en) 2000-05-11 2001-11-15 Basf Ag New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
IT1318641B1 (en) * 2000-07-25 2003-08-27 Novuspharma Spa AMID ACIDS 2- (1H-INDOL-3-IL) -2-OXO-ACETICS WITH ANTI-TUMOR ACTIVITY.
WO2003022280A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamideindoles for treating cancer
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
JP2003300382A (en) * 2002-04-08 2003-10-21 Konica Minolta Holdings Inc Imaging method using heat-transfer intermediate transfer medium
KR100645684B1 (en) * 2002-09-12 2006-11-15 에프. 호프만-라 로슈 아게 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes

Also Published As

Publication number Publication date
EP1280774A1 (en) 2003-02-05
DE10022925A1 (en) 2001-11-15
MXPA02010985A (en) 2003-04-25
CA2408369A1 (en) 2002-11-07
JP2003532709A (en) 2003-11-05
US7087637B2 (en) 2006-08-08
WO2001085687A1 (en) 2001-11-15
US20040067949A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2001274009A1 (en) Substituted indoles as parp inhibitors
AU2001258771A1 (en) -secretase inhibitors
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2002357003A1 (en) Indoles as naaladase inhibitors
AU3770000A (en) Indolinone compounds as kinase inhibitors
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2001231664A1 (en) Indol-3-yl derivatives
IL151154A0 (en) Indol-3-yl derivatives
AU2002213100A1 (en) Indole compounds as minimally physiologial function monitioring agents
AU2003277674A1 (en) Novel parp inhibitors
AU8664701A (en) Oxindole derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU5331499A (en) Indole spla2 inhibitors
AU2001230605A1 (en) Apoptosis inhibitor
AU2001244562A1 (en) Neovascularization inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001292241A1 (en) Benzodiazepine derivative
AU2001295455A1 (en) Indoline derivatives as 5ht2c antagonists
AU2002239263A1 (en) Tetracyclic carbazole derivates and their use as spla2 inhibitors
AU2001255408A1 (en) Tetrahydro-azepinone derivatives as thrombin inhibitors